S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:NUVA

NuVasive Stock Forecast, Price & News

$60.33
+1.83 (+3.13 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$56.93
Now: $60.33
$62.41
50-Day Range
$53.26
MA: $56.94
$59.95
52-Week Range
$28.55
Now: $60.33
$69.00
Volume1.19 million shs
Average Volume810,979 shs
Market Capitalization$3.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
NuVasive logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Employees2,800
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$5.91 per share
Book Value$17.58 per share

Profitability

Net Income$65.23 million

Miscellaneous

Market Cap$3.09 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

654th out of 1,960 stocks

Surgical & Medical Instruments Industry

75th out of 167 stocks

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$60.33
+1.83 (+3.13 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive
or view top-rated stocks.

What stocks does MarketBeat like better than NuVasive?

Wall Street analysts have given NuVasive a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NuVasive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings results on Thursday, February, 25th. The medical device company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. NuVasive had a negative net margin of 0.84% and a positive trailing twelve-month return on equity of 8.00%. During the same period last year, the firm posted $0.73 earnings per share.
View NuVasive's earnings history
.

How has NuVasive's stock been impacted by COVID-19 (Coronavirus)?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NUVA shares have increased by 22.1% and is now trading at $60.33.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NUVA?

16 equities research analysts have issued 1-year price objectives for NuVasive's stock. Their forecasts range from $48.00 to $74.00. On average, they expect NuVasive's stock price to reach $60.47 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for NuVasive
or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $2.43M)
  • Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $686.56k)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 51)
  • Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 41)
  • Mr. Johnson Lai, Chief Information Officer
  • Mr. Sean Freeman, Sr. VP of Strategy & Corp. Devel.
  • Mr. Lucas Vitale, Sr. VP & Chief HR Officer (Age 44)
  • Mr. Frank Middeke, Managing Director of DACH
  • Ms. Lisa Pecora, VP & Head of Global Commercial Fin.
  • Mr. Brent J. Boucher, Exec. VP of Global Commercial (Age 54)

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.91%), Dimensional Fund Advisors LP (2.26%), Anchor Capital Advisors LLC (2.19%), Victory Capital Management Inc. (2.09%), Fisher Asset Management LLC (1.84%) and Lord Abbett & CO. LLC (1.59%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which major investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Lord Abbett & CO. LLC, Nicholas Company Inc., ExodusPoint Capital Management LP, Anchor Capital Advisors LLC, Engineers Gate Manager LP, Victory Capital Management Inc., and Ziegler Capital Management LLC.
View insider buying and selling activity for NuVasive
or view top insider-selling stocks.

Which major investors are buying NuVasive stock?

NUVA stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Kennedy Capital Management Inc., New York State Common Retirement Fund, Principal Financial Group Inc., Principal Financial Group Inc., Armistice Capital LLC, Stephens Investment Management Group LLC, and Prospector Partners LLC.
View insider buying and selling activity for NuVasive
or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $60.33.

How much money does NuVasive make?

NuVasive has a market capitalization of $3.09 billion and generates $1.17 billion in revenue each year. The medical device company earns $65.23 million in net income (profit) each year or $2.47 on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,800 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.